Immunotherapy Allergy Shots: Who Should Choose SCIT and Why

Yes — allergy shots and immunotherapy refer to the same treatment when used in the allergy context. 'Allergy shots' is the common patient-facing term; 'subcutaneous immunotherapy' (SCIT) is the clinical term; 'allergen immunotherapy' (AIT) is the broader category that also includes sublingual tablets and drops. The word 'immunotherapy' has become associated with cancer treatment in popular culture, but allergy immunotherapy predates cancer immunotherapy by roughly 100 years — Noon and Freeman published the first SCIT protocol in 1911. When your allergist recommends immunotherapy for rhinitis or asthma, they are recommending either allergy shots or sublingual immunotherapy — not cancer treatment. The underlying mechanism (tolerance induction) differs fundamentally from cancer checkpoint inhibition.

Allergy shots are particularly well-suited for patients who are sensitized to multiple unrelated allergens that cannot be addressed by any single FDA-approved sublingual tablet — for example, a patient sensitized to cat dander, ragweed, and two mold species simultaneously. SCIT is the only modality that allows formulating custom multi-allergen vials. Shots are also preferable for patients with severe single-allergen disease where the sublingual data are thin (particularly cat dander), and for patients who benefit from supervised dosing with a clinician available to adjust the protocol. Patients with confirmed IgE-mediated sensitization, symptoms despite pharmacotherapy, and willingness to attend weekly-to-monthly clinic visits for 3-5 years are the clearest candidates per AAAAI/ACAAI Practice Parameter (Cox et al., JACI 2011).

Allergy shots and sublingual drops drive the same immune outcomes — Treg induction, IgG4 blocking antibodies, and reduced mast cell reactivity — but differ in delivery, safety profile, convenience, and regulatory status. SCIT requires clinic visits with a mandatory 30-minute post-injection observation period; sublingual drops are self-administered at home daily. SCIT has a systemic reaction rate of about 0.1% per injection with rare fatal outcomes; sublingual drops have no confirmed fatalities worldwide and predominantly cause mild local oral reactions. Nelson's 2015 network meta-analysis found no significant efficacy difference between SCIT and SLIT tablets for grass pollen. SCIT retains an advantage for polysensitized patients needing multi-allergen protocols, while drops offer superior convenience and safety for patients with one or a few allergens.

Most patients receiving allergy shots as immunotherapy notice symptom improvement within 3 to 6 months of starting — often coinciding with reaching the maintenance dose or completing their first pollen season on treatment. The AAAAI/ACAAI Practice Parameter (Cox et al., JACI 2011) states clinical improvement is usually observed within 1 year of reaching the maintenance dose. If no improvement occurs after 1 year at proper maintenance dosing, discontinuation should be considered. However, the full disease-modifying benefit — relief that persists 3-12 years after stopping — requires completing the minimum 3-year course. Patients who stop at 12-18 months experience temporary improvement rather than lasting remission; the GRASS trial (Scadding 2017) confirmed 2-year courses are insufficient for durable post-treatment benefit.

Real-world completion rates for allergy shots are strikingly lower than clinical trial rates. The most comprehensive real-world study, Kiel et al. (JACI 2013, Dutch pharmacy database, n=6,486), found only 23% of SCIT patients completed the minimum recommended 3-year duration, with a median persistence of just 1.7 years. The Florida Medicaid pediatric study (Hankin, Cox et al., JACI 2008, n=3,048 children) found 84% of children failed to complete 3 years and 53% stopped within the first year. Even in a US military cohort with zero out-of-pocket cost, only 34% completed 3 or more years (Mendoza, Ann Allergy 2023). The dominant reasons for discontinuation are inconvenience and time burden of clinic visits (40% in Vaswani 2015), cost, and perceived lack of early efficacy. Patients who do complete 3-5 years achieve the disease-modifying outcomes the evidence promises.

Traditionally, yes — allergy shots were administered only in a clinic where anaphylaxis could be immediately treated, and the AAAAI/ACAAI Practice Parameter (Cox et al., JACI 2011) describes administration in a setting with epinephrine and trained personnel plus a 30-minute observation period. That standard exists because approximately 85% of systemic reactions occur within 30 minutes of injection (Epstein et al., Ann Allergy 2011). Telehealth-based programs now make supervised at-home self-administration possible for eligible maintenance patients by reproducing those safeguards a different way: the first injection and every dose change are supervised live over Zoom by the prescribing physician, a prescribed epinephrine auto-injector is confirmed on hand before the first dose, the serum is sterile-compounded to USP <797> standards, and dosing escalates gradually under a board-certified allergist. (FDA-approved sublingual tablets are separately cleared for at-home use after a supervised first dose.)

Allergy shots have established efficacy for a wide range of IgE-mediated allergens. Evidence is strongest for grass pollens (51 RCTs in Calderon Cochrane 2007), house dust mites, ragweed, cat dander, birch pollen, and Alternaria mold. Evidence is moderate for other tree pollens, weeds, and dog dander. Evidence is weak or absent for cockroach (CRITICAL trial 2024 failed its primary endpoint), most molds other than Alternaria, and food allergens (food allergy is treated with oral immunotherapy, not SCIT). Hymenoptera venom (bee, wasp, yellow jacket stings) is treated with specialized venom immunotherapy — the most successful AIT modality, preventing systemic reactions in 95-98% of patients. One key SCIT advantage over FDA-approved tablets is the ability to formulate custom vials combining multiple allergens from different categories for polysensitized patients.